Clarity Pharmaceuticals Says Sydney Hospital to Start Trial of Its Prostate Cancer Diagnostic Product; Shares Fall 10%
MT Newswires Live
Nov 18, 2024
Clarity Pharmaceuticals Ltd (ASX:CU6) said St Vincent's Hospital in Sydney will launch a phase 2 trial to compare its copper-based radiopharmaceutical diagnostic product, 64Cu-SAR-bis-PSMA, with the standard of care, gallium-based 68Ga-PSMA-11, according to a Monday filing with the Australian bourse.
The trial will enroll 50 patients and test the detection rates of the products for sites of prostate cancer recurrence based on positron emission tomography or computed tomography scans, the filing said.
Company shares fell nearly 10% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.